Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 11/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.59 |
| ▸ | ACHE | P22303 | 2/20 | 0.59 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | CNR1 | P21554 | 1/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.59 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.59 |
| ▸ | MC3R | P41968 | 1/20 | 0.59 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.59 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.59 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.59 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | TNF | P01375 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL316760 | 0.88 | ADORA2B (1.00) | ADORA2BGLABLMADORA3ACHE | |
| SCHEMBL22342560 | 0.87 | ADORA2B (0.77) | ADORA2BGLABLMADORA3ACHE | |
| SCHEMBL17737315 | 0.85 | ADORA2B (1.00) | ADORA2BGLABLMADORA3ACHE | |
| SCHEMBL18255999 | 0.85 | ADORA2B (0.73) | ADORA2BGLABLMADORA3ACHE | |
| SCHEMBL11305914 | 0.83 | ADORA2B (0.71) | ADORA2BGLABLMACHEADORA2A | |
| SCHEMBL10018599 | 0.83 | ADORA2B (0.72) | ADORA2BGLABLMADORA3ACHE | |
| Bisdionin C SCHEMBL10018600 | 0.81 | CHIT1 (0.75) | ADORA2BGLABLMADORA3ACHE | |
| SCHEMBL516446 | 0.81 | ADORA2A (0.74) | ADORA2BGLABLMADORA3ACHE | |
| Bisdionin D SCHEMBL16120988 | 0.81 | ADORA2B (0.79) | ADORA2BGLABLMADORA3ACHE | |
| SCHEMBL16192700 | 0.81 | ADORA2B (0.68) | ADORA2BGLABLMADORA2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025132845-A1 | GALNAC PHOSPHORAMIDITES AND THEIR USES | SILENCE THERAPEUTICS GMBH (DE) | 2025-06-26 | — | — | WO | claimed |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | claimed |
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | claimed |
| WO-2023039578-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION (US) | 2023-03-16 | — | — | WO | claimed |
| WO-2022023496-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2022-02-03 | — | — | WO | claimed |
| US-20200182859-A1 | HDAC1/2 ACTIVATOR FOR PROMOTING AND/OR ACCELERATING MYELINATION AND/OR REMYELINATION | UNIVERSITE DE FRIBOURG (CH) | 2020-06-11 | — | — | US | claimed |
| EP-3412294-A1 | HDAC1/2 ACTIVATOR FOR PROMOTING AND/OR ACCELERATING MYELINATION AND/OR REMYELINATION | Universite De Fribourg (CH) | 2018-12-12 | — | — | EP | claimed |
| US-8193201-B2 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | METAPROTEOMICS, LLC (US) | 2012-06-05 | — | — | US | claimed |
| US-8188063-B2 | A2A receptor agonists for the central nervous system; antiinflammatory agents; 2,7-disubstituted-5-amino-pyrazolo[4,3-e]-[1,2,4]-triazolo[1,5-c]pyrimidines, mefloquine, 8-(3-chlorostyryl)caffeine, 3,7,8-trisubstituted-1-propargyl-xanthines; 2,5-disubstituted-7-amino-[1,2,4]triazolo[1,5-a][1,3,5]triazines | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-29 | — | — | US | claimed |
| US-20120052005-A1 | COMBINATION THERAPY TO IMPROVE DRUG EFFICIENCY | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-03-01 | — | — | US | claimed |
| US-20070185213-A1 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | WHITEHORSE CAPITAL ORIGINATION, LLC, AS AGENT | 2007-08-09 | — | — | US | claimed |
| EP-1718312-A2 | SYNERGISTIC ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS USING CURCUMINOIDS OR METHYLXANTHINES | Metaproteomics, LLC (US) | 2006-11-08 | — | — | EP | claimed |
| US-20060128708-A1 | Antagonizing an adenosine A2A receptor to ameliorate one or more components of addictive behavior | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2006-06-15 | — | — | US | claimed |
| WO-2005084230-A2 | SYNERGISTIC ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS USING CURCUMINOIDS OR METHYLXANTHINES | METAPROTEOMICS, LLC (US) | 2005-09-15 | — | — | WO | claimed |
| US-20050191375-A1 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | WHITEHORSE CAPITAL ORIGINATION, LLC, AS AGENT | 2005-09-01 | — | — | US | claimed |
| US-20050148067-A1 | Materials and methods for binding nucleic acids to surfaces | LYLES MARK B (US) | 2005-07-07 | — | — | US | claimed |
| US-6855817-B2 | Materials and methods for binding nucleic acids to surfaces | LYLES MARK B (US) | 2005-02-15 | — | — | US | claimed |
| US-6710051-B1 | SUBSTANCES IS A XANTHINE AND IS ADMINISTERED IN A DOSAGE OF 7.5-750 MG 1-4 TIMES DAILY TO TREAT MYOPIA | KLAUS TRIER APS (DK) | 2004-03-23 | — | — | US | claimed |
| US-20040013609-A1 | For identification of substances for treatment or prevention of insufficient longitudinal growth of eye(hypermetropia) or excessive longitudinal growth of eye(myopia); involves measurement of effect on retinal pigment epithelium | TRIER KLAUS (DK) | 2004-01-22 | — | — | US | claimed |
| US-20020103350-A1 | Materials and methods for binding nucleic acids to surfaces | LYLES MARK B (US) | 2002-08-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185213-A1 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | HMOX1, HMOX2, HPGDS | ADORA2B 1339/4885GLA 3687/4885BLM 3909/4885 |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | TP53, CD4, MCL1 | ADORA2B 2902/4885GLA 525/4885BLM 967/4885 |
| US-20040013609-A1 | For identification of substances for treatment or prevention of insufficient longitudinal growth of eye(hypermetropia) or excessive longitudinal growth of eye(myopia); involves measurement of effect on retinal pigment epithelium | RYR1, ATP2A2, ATP2A1 | ADORA2B 826/4885GLA 648/4885BLM 3384/4885 |
| US-20120052005-A1 | COMBINATION THERAPY TO IMPROVE DRUG EFFICIENCY | ABCG2, ABCB1, ABCC1 | ADORA2B 389/4885GLA 3262/4885BLM 679/4885 |
| US-20050191375-A1 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | HMOX1, HMOX2, HPGDS | ADORA2B 1339/4885GLA 3687/4885BLM 3909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.